MapLight Therapeutics, Inc. (MPLT) stock
Close on Nov 17, 2026Market cap $304.70MP/E –Yield –
Earnings
MapLight Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of MapLight Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Dec 3, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | – | – | -$1.34 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026before the open | – | – | -$2.47 | Release |
| Q3 FY2025ended Sep 30, 2025 | Dec 4, 2025before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
MapLight Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When MapLight Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases MapLight Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?